Lilly and Merck Lead the Way With Asian FIPNet Strategies
Executive Summary
There's a new acronym to learn:FIPNet--for fully integrated pharmaceutical network. Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality research available in India and China--countries that also should prove to be a major source of future customers. Merck and Eli Lilly are two companies leading the FIPNet charge.
You may also be interested in...
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
BGI Touts Eventual Merck Deal
Beijing Genomics and Merck intend to collaborate, using BGI resources primarily to analyze genomic and epigenetic data off of Merck samples. The announcement was more than just a shot across the bow signaling BGI's intent to dominate the gene sequencing services world. It could eventually extend into the clinical arena, which could open up another whole new collaborative - and competitive - area with the West.